Rx Rogaine study on hemodynamic effects provided sufficient OTC safety data -- Temple.
This article was originally published in The Tan Sheet
Executive Summary
Rx ROGAINE STUDY OUTLINING TOPICAL MINOXIDIL DOSE/RESPONSE versus oral minoxidil, "six benign...years of marketing," and a post-marketing study "indicate a very satisfactory record of safety...suitable for an OTC drug," FDA Office of Drug Evaluation I Director Robert Temple, MD, concluded in a March 20 memo. Addressed to Center for Drug Evaluation and Research Director Janet Woodcock, MD, the 19-page memo outlines Temple's thoughts on why an I.V. minoxidil safety study conducted by Upjohn in support of the Rogaine switch was not essential for FDA approval.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning